- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT05400265
Evaluate the Safety, Tolerability, Pharmacokinetic Characteristics and Preliminary Efficacy of HLX26 and HLX10 in Patients With Advanced/Metastatic Solid Tumor
February 4, 2024 updated by: Shanghai Henlius Biotech
A Phase I Clinical Study to Evaluate the Safety, Tolerability, Pharmacokinetic Characteristics and Preliminary Efficacy of HLX26 Monoclonal Antibody Injection in Combination With HLX10 Monoclonal Antibody Injection in Patients With Advanced/Metastatic Solid Tumor
This study is a open-label, phase I, dose escalation clinical study to evaluate the safety and tolerability of HLX26 and HLX10 in the treatment of patients with advanced/metastatic solid tumors.
Study Overview
Detailed Description
This study is a open-label, phase I, dose escalation clinical study to evaluate the safety and tolerability of HLX26 and HLX10 in the treatment of patients with advanced/metastatic solid tumors.
In this study, a 3 + 3 dose escalation design was used.
The patients will be given different doses(500mg, 800mg Q3W) of HLX26 Plus fixed dose of HLX10(300mg) intravenously.
Observation period of DLT lasts for 3 weeks after the first administration of HLX26.
Study Type
Interventional
Enrollment (Actual)
9
Phase
- Phase 1
Contacts and Locations
This section provides the contact details for those conducting the study, and information on where this study is being conducted.
Study Contact
- Name: Yumei Yang
- Phone Number: 021-33395800*6541
- Email: yumei_yang@henlius.com
Study Contact Backup
- Name: Ni Zhang
- Email: ni_zhang@henlius.com
Study Locations
-
-
Jiangsu
-
Xuzhou, Jiangsu, China
- Xuzhou Central Hospital
-
-
Participation Criteria
Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.
Eligibility Criteria
Ages Eligible for Study
18 years to 75 years (Adult, Older Adult)
Accepts Healthy Volunteers
No
Description
Inclusion Criteria:
- Have a full understanding of the study content, process, and possible adverse reactions before the study, and sign the informed consent form (ICF); voluntarily participate in the study; be able to complete the study as per protocol requirements;
- Aged ≥ 18 years and ≤75 years at the time of signing the ICF;
- Patients with histologically or cytologically confirmed advanced malignant solid tumor who have failed or cannot receive the standard treatment;
- With at least one measurable lesion according to RECIST V1.1 (for solid tumors);
- Eastern Cooperative Oncology Group (ECOG) performance status score of ≤ 1 at enrollment;
- Expected survival > 3 months;
- Patients with Non-Small Cell Lung Cancer had no EGFR sensitivity mutation or gene rearrangement or jump of ALK, ROS1, RET and METex14;
- For patients with hepatocellular carcinoma, Child-Pugh score has to be A;
- Have appropriate hematological functions: no blood transfusion or Treatment for hemocytopenia within 14 days before the first administration; absolute neutrophil count ≥ 1500/μL; haemoglobin ≥ 9 g/dL; platelet count ≥ 90,000/μL;
- Have appropriate coagulation functions: activated partial thromboplastin time (APTT) ≤ 1.5 × ULN; prothrombin time (PT) ≤ 1.5 × ULN; international normalized ratio (INR) ≤ 1.5 × ULN;
- Have appropriate liver functions: total bilirubin level ≤ 1.5 × ULN, aspartate aminotransferase (AST) and alanine aminotransferase (ALT) levels ≤ 2.5 × ULN (AST and ALT ≤ 5 × ULN for patients with known liver metastasis or primary hepatocellular carcinoma);
- Have appropriate renal functions: blood creatinine ≤ 1.5 × ULN or creatinine clearance ≥ 50 mL/min (calculated by Cockcroft-Gault formula);
- The first administration of the investigational product must be: at least 28 days apart from the previous major surgery, medical device treatment, or local radiotherapy; at least 28 days apart from the previous cytotoxic chemotherapy, immunotherapy, and biological agent therapy; at least 14 days apart from the previous hormone therapy and surgical operation; at least 21 days or 5 half-lives apart from the administration of small molecule targeted drugs, whichever is longer; at least 14 days apart from the traditional Chinese medicine for tumor indications; at least 14 days apart from the endocrine therapy; For any drug with antitumor effect not listed above, at least 5 half lives shall be separated before administration of the first study drug;
- Male and female subjects with child-bearing potential must agree to use at least one highly effective contraception method during the study and within at least 6 months after the last administration of the investigational product.
Exclusion Criteria:
- The adverse reactions (except alopecia and other adverse reactions determined by the investigator to have no safety risk) of previous anti-tumor therapy have not yet recovered to ≤ grade 1 (CTCAE V5.0);
- Those who are known to have severe anaphylaxis (grade 4 or greater in CTCAE V5.0) to macromolecular protein preparations/monoclonal antibodies or to any component of the investigational product;
- Patients with any of the following unstable or poorly controlled diseases:1)Active systemic infectious diseases requiring intravenous antibiotics within 2 weeks before the first administration of the investigational product;2)Any poorly-controlled cardiovascular and cerebrovascular clinical symptoms or diseases, including but not limited to: (1) NYHA Class II or greater cardiac failure or left ventricular ejection fraction (LVEF) < 50%; (2) unstable angina pectoris; (3) myocardial infarction and cerebral infarction within 6 months, (4) clinically significant supraventricular or ventricular arrhythmia without clinical intervention or poorly controlled after clinical intervention;3)Other chronic diseases which, in the opinion of the investigator, may compromise the safety of the patient or the integrity of the study;
- Assessed as unsuitable for inclusion by the investigator, due to brain metastases, spinal cord compression, or cancerous meningitis with clinical symptoms, or uncontrolled brain or spinal cord metastases that have been evidenced;
- Previous grade 3 or greater irAEs in immunotherapy;
- Have had other malignant tumors within 5 years before enrollment, except: (a) those with cured cervical carcinoma in situ or non-melanoma skin cancer; (b) those with cured second primary cancer without recurrence within 5 years; (c) those with double primary cancers believed to be able to benefit from this study; (d) those whose metastasis has been clearly excluded from a certain primary tumor source;
- those who have received anti-LAG-3 antibody therapy;
- Have active autoimmune diseases (including but not limited to the following diseases or syndromes, such as interstitial pneumonia, colitis, hepatitis, hypophysitis, vasculitis, nephritis, hyperthyroidism, and hypothyroidism), except: vitiligo or cured childhood asthma/allergy that does not need any intervention in adulthood, autoimmune mediated hypothyroidism treated with stable dose of thyroid replacement hormone, and type I diabetes treated with stable dose of insulin; those in a stable condition and requiring no systemic immunosuppressant therapy (including corticosteroid hormone) are allowed to be enrolled;
- Have received systemic corticosteroids (prednisone > 10 mg/d or equivalent dose of similar drug) or other immunosuppressants within 14 days before the first administration; Except: patients treated with topical, ocular, intra-articular, intranasal, and inhaled corticosteroids; those with short term use of corticosteroids for prophylaxis, such as contrast agents;
- Patients in pregnancy [confirmed by serum beta-human chorionic gonadotropin (ß-HCG) test] or breastfeeding;
- With a history of immunodeficiency, including human immunodeficiency virus (HIV)-positive or other acquired or congenital immunodeficiencies, or a history of organ transplantation;
- Patients with active HBV or HCV infection (HBV DNA ≥ 10*4 copies/mL or positive HCV RNA, but patients with HBV DNA < 10*4 copies / mL after treatment will be excluded); Subjects with co-infection of hepatitis B and hepatitis C (HBsAg or HBcAb positive, and HCV antibody positive);
- Have received live vaccines within 28 days prior to the first administration;
- Interstitial pneumonia occurred during previous anti-tumor treatment;
- Patients whose medical history or any other evidence suggests that participation in the study may confuse the results, or subjects for whom the investigator believes the study is not in their best interest;
- Participating in other clinical studies or less than 14 days from the end of the treatment of the previous clinical study.
Study Plan
This section provides details of the study plan, including how the study is designed and what the study is measuring.
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: Non-Randomized
- Interventional Model: Sequential Assignment
- Masking: None (Open Label)
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Experimental: Dose Cohort 1
In this cohort, the dose of HLX26 is 500mg.
HLX26 will be intravenously administered every 3 weeks.
HLX10 will be intravenously administered every 3 weeks with the fixed dose of 300mg.
Patients will receive the treatment until they have been in therapy for 2 years, develop progressive disease (PD) without any clinical benefit, death, intolerable toxicity, or withdraw the informed consent (whichever occurs first).
|
Humanized Anti-Lymphocyte Activation Gene-3 Monoclonal Antibody
Other Names:
Humanized Anti-Programmed Death-1 Monoclonal Antibody
Other Names:
|
Experimental: Dose Cohort 2
In this cohort, the dose of HLX26 is 800mg.
HLX26 will be intravenously administered every 3 weeks.
HLX10 will be intravenously administered every 3 weeks with the fixed dose of 300mg.
Patients will receive the treatment until they have been in therapy for 2 years, develop progressive disease (PD) without any clinical benefit, death, intolerable toxicity, or withdraw the informed consent (whichever occurs first).
|
Humanized Anti-Lymphocyte Activation Gene-3 Monoclonal Antibody
Other Names:
Humanized Anti-Programmed Death-1 Monoclonal Antibody
Other Names:
|
Experimental: Dose Cohort 3
In this cohort, the dose of HLX26 is 1600mg.
HLX26 will be intravenously administered every 3 weeks.
HLX10 will be intravenously administered every 3 weeks with the fixed dose of 300mg.
Patients will receive the treatment until they have been in therapy for 2 years, develop progressive disease (PD) without any clinical benefit, death, intolerable toxicity, or withdraw the informed consent (whichever occurs first).
|
Humanized Anti-Lymphocyte Activation Gene-3 Monoclonal Antibody
Other Names:
Humanized Anti-Programmed Death-1 Monoclonal Antibody
Other Names:
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
DLT
Time Frame: from day1 to day 21
|
The Dose-Limiting Toxicity (DLT) of HLX26 in combination with HLX10 within 3 weeks after the first Administration in patients with Advanced/Metastatic Solid Tumors
|
from day1 to day 21
|
MTD
Time Frame: from day1 to day 21
|
The Maximum Tolerated Dose (MTD) of HLX26 in combination with HLX10 within 3 weeks after the first Administration in patients with Advanced/Metastatic Solid
|
from day1 to day 21
|
Collaborators and Investigators
This is where you will find people and organizations involved with this study.
Sponsor
Study record dates
These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.
Study Major Dates
Study Start (Actual)
July 26, 2022
Primary Completion (Actual)
August 31, 2023
Study Completion (Actual)
January 31, 2024
Study Registration Dates
First Submitted
May 23, 2022
First Submitted That Met QC Criteria
May 28, 2022
First Posted (Actual)
June 1, 2022
Study Record Updates
Last Update Posted (Estimated)
February 6, 2024
Last Update Submitted That Met QC Criteria
February 4, 2024
Last Verified
February 1, 2024
More Information
Terms related to this study
Keywords
Additional Relevant MeSH Terms
Other Study ID Numbers
- HLX26-002
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
NO
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
No
Studies a U.S. FDA-regulated device product
No
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Adult Solid Tumor
-
Memorial Sloan Kettering Cancer CenterRecruitingSolid Tumor | Solid Tumor, Adult | Solid Tumor, Unspecified, AdultUnited States
-
Memorial Sloan Kettering Cancer CenterLincoln Medical and Mental Health CenterRecruitingSolid Tumor | Solid Tumor, Adult | Solid Tumor, Unspecified, AdultUnited States, Puerto Rico
-
Memorial Sloan Kettering Cancer CenterLincoln Medical and Mental Health CenterRecruitingSolid Tumor | Solid Tumor, Adult | Solid Tumor, Unspecified, AdultUnited States, Puerto Rico
-
Shenzhen Ionova Life Sciences Co., Ltd.Merck Sharp & Dohme LLCRecruitingCancer | Solid Tumor, Adult | Solid Carcinoma | Solid Tumor, Unspecified, Adult | Cancer Metastatic | Tumor, SolidUnited States
-
Partner Therapeutics, Inc.WithdrawnSolid Tumor | Solid Tumor, AdultUnited States
-
Invitae CorporationRecruitingCancer | Solid Tumor | Solid Tumor, AdultUnited States
-
Sairopa B.V.RecruitingMetastatic Solid Tumor | Solid Tumor, Adult | Refractory CancerUnited States, Moldova, Republic of
-
Institut CurieRecruitingChemotherapy Effect | Solid Tumor, Adult | Solid Tumor, ChildhoodFrance
-
New York Stem Cell Foundation Research InstituteStevens Institute of TechnologyRecruiting
-
JemincareNot yet recruiting
Clinical Trials on HLX26
-
Shanghai Henlius BiotechCompleted
-
Shanghai Henlius BiotechSuspendedColorectal Cancer MetastaticChina
-
Shanghai Henlius BiotechRecruiting